Charles River Laboratories Rating Lowered to Hold at TheStreet (CRL)
Separately, analysts at Sterne Agee raised their price target on shares of Charles River Laboratories to $45.00 in a research note to investors on Monday, April 2nd.
Charles River Laboratories traded down 0.68% on Monday, hitting $33.62. Charles River Laboratories has a 1-year low of $25.52 and a 1-year high of $42.84. The company has a market cap of $1.647 billion and a price-to-earnings ratio of 16.19.
Charles River Laboratories last released its earnings data on Wednesday, May 2nd. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. The company’s revenue for the quarter was up .0% on a year-over-year basis. Analysts expect that Charles River Laboratories will post $0.66 EPS next quarter.
Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced pre-clinical services.